Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Short term Debt (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Short term Debt for 13 consecutive years, with $34.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt rose 841.96% to $34.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $34.0 million, a 841.96% increase, with the full-year FY2024 number at $37.0 million, up 530.76% from a year prior.
  • Short term Debt was $34.0 million for Q3 2025 at Harvard Bioscience, down from $34.9 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $37.0 million in Q4 2024 to a low of $2.0 million in Q1 2021.
  • A 5-year average of $10.0 million and a median of $3.5 million in 2023 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: dropped 29.82% in 2021, then skyrocketed 866.61% in 2025.
  • Harvard Bioscience's Short term Debt stood at $3.2 million in 2021, then rose by 17.81% to $3.8 million in 2022, then soared by 53.74% to $5.9 million in 2023, then soared by 530.76% to $37.0 million in 2024, then decreased by 8.09% to $34.0 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Short term Debt are $34.0 million (Q3 2025), $34.9 million (Q2 2025), and $36.0 million (Q1 2025).